Market Overview:
The global blood-thinning drugs market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of cardiovascular diseases, rising geriatric population, and technological advancements in the field of blood-thinning drugs. The global blood-thinning drugs market is segmented on the basis of type into anticoagulants and antiplatelet drugs. The anticoagulants segment is further subsegmented into injectable blood thinners and oral blood thinners. The oral antiplatelet agents segment is further subsegmented into aspirin, clopidogrel bisulfate, prasugrel hydrochloride, ticlopidine hydrochloride, and others (gabapentin enacarbil). In terms of application, the global blood-thinning drugs market is divided into two segments: prophylaxis and treatment. The prophylaxis segment accounts for a larger share in terms of revenue as compared to the treatment segment owing to early diagnosis & prevention measures for various disorders such as heart attack or stroke that can lead to death or disability.
Product Definition:
Blood-thinning drugs, also called anticoagulants, are a type of medication that helps to prevent blood clots from forming. This is important because blood clots can cause problems such as heart attacks and strokes.
Anticoagulants:
Anticoagulants are substances that reduce the coagulation of blood. They do not prevent clotting but rather delay it for a while. Anticoagulants lower the normal blood clotting time by interfering with the mechanism that causes bleeding. Some anticoagulant drugs also limit the amount of damage to vital organs, such as kidneys and liver, caused by too much blood loss during surgery or treatment.
Antiplatelet Drugs:
Antiplatelet drugs are a group of medications used to prevent blood clots from forming in the arteries. They work by decreasing the platelets aggregation or by removing already formed blood clots from the artery. Antiplatelet drugs can be divided into two types: anticoagulants and anti-thrombotic agents. Anticoagulants include warfarin, heparins, and xanthine oxidase inhibitors (XRIs).
Application Insights:
Injectable blood thinners dominated the global market and accounted for a revenue share of around 47.0% in 2017 owing to its high usage rate in surgeries, especially cardiovascular procedures. Moreover, increasing cases of deep vein thrombosis (DVT) and pulmonary embolism (PE) are expected to boost the injectable drugs segment over the forecast period.
Owing to rising awareness among individuals regarding risk factors associated with venous thromboembolism (VTE), such as immobility and hospitalization due to acute illness or trauma along with increased prevalence of VTEs caused by immobilization or prolonged bed rest, oral anticoagulants are anticipated register lucrative growth during the forecast period. This is supported by favorable reimbursement policies that encourage healthcare professionals towards its use owing to low incidence rate compared Venous Thromboembolism (VTE).
Regional Analysis:
North America dominated the global blood-thinning drugs market in 2017. The presence of key players, favorable government initiatives, and increasing healthcare expenditure are some of the major factors contributing to its growth. In 2014, according to a study published in JAMA Internal Medicine by researchers from Harvard Medical School and Broad Institute of MIT, every dollar spent on prevention generates a return of more than two dollars through avoided costs for health care. Thusly it is concluded that investing more money on primary prevention will save huge amounts in future healthcare costs associated with cardiovascular diseases (CVDs).
The Asia Pacific region is expected to witness lucrative growth over the forecast period owing to rising incidence rates coupled with growing aging population especially in Japan & China & India & Australia who are at high risk for CVDs due to genetic mutations or lifestyle changes such as smoking or alcohol consumption which increases CVD vulnerability.
Growth Factors:
- Increasing incidence of cardiovascular diseases (CVDs) is expected to drive the demand for blood-thinning drugs over the forecast period.
- Growing geriatric population is also anticipated to boost the demand for these drugs as they are more susceptible to CVDs.
- Rising awareness about the benefits of blood thinners is projected to propel their uptake in both developed and developing countries.
- Technological advancements in manufacturing process of these drugs are likely to result in reduced side effects, which will further increase their adoption rates across the globe. 5
Scope Of The Report
Report Attributes
Report Details
Report Title
Blood-thinning Drugs Market Research Report
By Type
Anticoagulants, Antiplatelet Drugs
By Application
Injectable Blood Thinners, Oral Blood Thinners
By Companies
Bayer, Pfizer, Merck, Sanofi, Abbott, Johnson and Johnson, Baxter, AstraZeneca, Bayer
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
219
Number of Tables & Figures
154
Customization Available
Yes, the report can be customized as per your need.
Global Blood-thinning Drugs Market Report Segments:
The global Blood-thinning Drugs market is segmented on the basis of:
Types
Anticoagulants, Antiplatelet Drugs
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Injectable Blood Thinners, Oral Blood Thinners
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Bayer
- Pfizer
- Merck
- Sanofi
- Abbott
- Johnson and Johnson
- Baxter
- AstraZeneca
- Bayer
Highlights of The Blood-thinning Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Anticoagulants
- Antiplatelet Drugs
- By Application:
- Injectable Blood Thinners
- Oral Blood Thinners
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Blood-thinning Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Blood-thinning drugs are medications that help to reduce the amount of blood in the body. This can help to prevent serious bleeding episodes.
Some of the major companies in the blood-thinning drugs market are Bayer, Pfizer, Merck, Sanofi, Abbott, Johnson and Johnson, Baxter, AstraZeneca, Bayer.
The blood-thinning drugs market is expected to register a CAGR of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Blood-thinning Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Blood-thinning Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Blood-thinning Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Blood-thinning Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Blood-thinning Drugs Market Size & Forecast, 2020-2028
4.5.1 Blood-thinning Drugs Market Size and Y-o-Y Growth
4.5.2 Blood-thinning Drugs Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Anticoagulants
5.2.2 Antiplatelet Drugs
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Injectable Blood Thinners
6.2.2 Oral Blood Thinners
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Blood-thinning Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Blood-thinning Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Anticoagulants
9.6.2 Antiplatelet Drugs
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Injectable Blood Thinners
9.10.2 Oral Blood Thinners
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Anticoagulants
10.6.2 Antiplatelet Drugs
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Injectable Blood Thinners
10.10.2 Oral Blood Thinners
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Anticoagulants
11.6.2 Antiplatelet Drugs
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Injectable Blood Thinners
11.10.2 Oral Blood Thinners
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Anticoagulants
12.6.2 Antiplatelet Drugs
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Injectable Blood Thinners
12.10.2 Oral Blood Thinners
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Anticoagulants
13.6.2 Antiplatelet Drugs
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Injectable Blood Thinners
13.10.2 Oral Blood Thinners
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Blood-thinning Drugs Market: Competitive Dashboard
14.2 Global Blood-thinning Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Bayer
14.3.2 Pfizer
14.3.3 Merck
14.3.4 Sanofi
14.3.5 Abbott
14.3.6 Johnson and Johnson
14.3.7 Baxter
14.3.8 AstraZeneca
14.3.9 Bayer
